Coronary Artery Disease Clinical Trial
Official title:
APPRAISAL Trial: A Phase IIa Study to Evaluate the Safety and Preliminary Efficacy of RESTEN-MP® When Used in Conjunction With a Bare Metal Stent in de Novo Native Coronary Artery Lesions
The process of re-narrowing of a coronary artery following a revascularization procedure
such as angioplasty, begins at the time of the procedure. Restenosis has long been
considered a major problem for effective long-term interventional success. This often
results in repeated procedures to deal with recurrent stenosis (or restenosis) of the
original targeted vessel.
There is a substantial body of literature suggesting that local MYC protein production in
the injured coronary artery is a major stimulus and potential cause of restenosis that
appears after stent placement. This study is based upon the hypothesis that stopping MYC
protein production in the vessel will help reduce restenosis (vessel re-narrowing).
AVI BioPharma Inc., has utilized its proprietary antisense chemistry to design a drug that
interferes with MYC production.
This study will evaluate the safety and potential effectiveness of RESTEN-MP to reduce
in-stent restenosis following balloon angioplasty and stent placement. The post-dose
follow-up period is up to six-months.
RESTEN-MP is administered at the time a stent is successfully placed in a coronary artery,
and again 24 hours later, via slow-push intravenous administration.
Status | Completed |
Enrollment | 50 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. = 18 years of age. 2. An acceptable candidate for percutaneous transluminal coronary angioplasty (PTCA), coronary artery stenting, and emergent coronary artery bypass graft (CABG). 3. Clinical evidence of ischemic heart disease or a positive functional study. 4. The target lesion/vessel must meet the following criteria: 1. The target lesion is a single de novo lesion that has not been previously treated with any interventional procedure. Only one lesion may be treated per subject. 2. The target vessel must be a native coronary artery with a stenosis of = 50% and < 100%. 3. The target lesion must be = 10 mm and = 30 mm in length. 4. The target vessel reference diameter must be = 2.5 mm and = 4.0 mm. 5. Female subjects of childbearing potential must have a documented negative serum pregnancy test within seven days before the procedure. 6. The subject or the subject’s legally authorized representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site. 7. The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits. 8. The subject is capable of providing informed consent and has provided written consent prior to study entry. Exclusion Criteria: 1. Documented left ventricular ejection fraction < 30%. 2. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, stainless steel, or sensitivity to contrast media, which cannot be adequately pre-medicated. 3. Evidence of an acute myocardial infarction within 72 hours of the intended treatment [defined as: Q wave or non-Q wave infarction having creatine kinase (CK) enzymes = 2 times the upper laboratory normal (with the presence of a CK-MB elevated above the Institution’s upper limit of normal)] or acute myocardial infarction in progress at time of treatment. 4. Previous coronary interventional procedure of any kind within the 30 days prior to the stent-placement procedure. 5. Planned interventional treatment of either the target or any non-target vessel within 30 days post-stent placement procedure is required. 6. Target lesion requires treatment with a device other than PTCA prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, or rotational atherectomy). 7. Previous stenting anywhere in the target vessel. 8. Target vessel has evidence of thrombus or is excessively tortuous (2 bends > 90° to reach the target lesion). 9. Target lesion has any one of the following characteristics: 1. Lesion location is aorto-ostial, an unprotected left main lesion, or within 5 mm of the origin of the left anterior descending coronary artery (LAD), left circumflex coronary artery (LCX), or right coronary artery (RCA); 2. Involves a side branch > 2.0 mm in diameter; 3. Is at or distal to a 45º bend in the vessel; or 4. Is moderately to severely calcified. 10. History of a stroke or transient ischemic attack within the prior 6 months. 11. Active peptic ulcer or has had upper gastrointestinal (GI) bleeding within the prior 6 months. 12. History of a bleeding diathesis or coagulopathy or will refuse blood transfusions. 13. Concurrent medical condition with a life expectancy of less than 12 months. 14. Any previous or planned treatment with other anti-restenosis therapies including, but not limited to, brachytherapy in the target vessel within 30 days of the stent placement procedure. [Note: Staged treatment of a non-target vessel is appropriate 30 days after enrollment.] 15. Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. [Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.] 16. Unable to provide informed consent. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Coburg Hospital - Cardiology Clinic | Coburg | |
Germany | Cardiology Clinic, University Hospital of Essen | Essen | |
Germany | University Hospital of Heidelberg, Cardiology Clinic | Heidelberg |
Lead Sponsor | Collaborator |
---|---|
Sarepta Therapeutics | Harvard Clinical Research Institute |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate the potential efficacy of RESTEN-MP given intravenously upon confirmation of stent implantation and again at 24 hours post-stent implantation | |||
Primary | The therapeutic endpoint to assess potential efficacy is the prevention of coronary late lumen loss 6 months after the stent placement procedure, based on quantitative coronary angiography (QCA). | |||
Secondary | Major adverse cardiac events (MACE) defined as cardiac death, MI (Q wave and non-Q wave), emergent cardiac bypass surgery, and clinically-driven target lesion revascularization (TLR) at Days 14 and 30, and Month 6, 9 and 12 post-stent placement | |||
Secondary | Target vessel failure (TVF) rate, defined as a composite of target vessel revascularization, recurrent MI (Q or Non Q-Wave), or cardiac death that could not be clearly attributed to a vessel other than the target vessel at Month 9 post-stent placement | |||
Secondary | Angiographic binary restenosis (= 50% diameter stenosis) at Month 6 post-stent placement | |||
Secondary | In-stent minimum lumen diameter (MLD) at Month 6 post-stent placement | |||
Secondary | In-segment MLD at Month 6 post-stent placement | |||
Secondary | Proximal and distal late loss at Month 6 post-stent placement. | |||
Secondary | In-stent and in-segment percent (%) diameter stenosis at Month 6 post-stent placement |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |